Experienced in Leukemia

Dr. Connie W. Batlevi

Oncology
1275 York Ave, Box 330, 
New York, NY 
Clinical Trials:Currently Recruiting for 2 Trials
Experienced in Leukemia
1275 York Ave, Box 330, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Connie Batlevi is an Oncologist in New York, New York. Dr. Batlevi is rated as an Experienced provider by MediFind in the treatment of Leukemia. Her top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 63 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles in the study of Leukemia.

Specialties
Oncology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

1275 York Ave, Box 330, New York, NY 10065

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Combination product, Drug
Study Drugs: Tazemetostat, Lenalidomide, Rituximab
Study Phase: Phase 3
An Exploratory Study to Correlate the Level of Cell-free DNA With Response to First-line Treatment in Patients With Follicular Lymphoma
An Exploratory Study to Correlate the Level of Cell-free DNA With Response to First-line Treatment in Patients With Follicular Lymphoma
Enrollment Status: Recruiting
Publish Date: August 19, 2025
Intervention Type: Diagnostic test, Other
Study Phase: Phase 1
A Single Arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 With Anti Programmed Cell Death Protein 1 (PD1) Antibody in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
A Single Arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 With Anti Programmed Cell Death Protein 1 (PD1) Antibody in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Enrollment Status: Terminated
Publish Date: July 14, 2025
Intervention Type: Biological
Study Drugs: AUTO3, cyclophosphamide, fludarabine, pembrolizumab
Study Phase: Phase 1/Phase 2
Phase I Study of N-Acetylcysteine to Optimize Metabolic Tumor Microenvironment in CD19 CAR T-cell Therapy in Lymphoma
Phase I Study of N-Acetylcysteine to Optimize Metabolic Tumor Microenvironment in CD19 CAR T-cell Therapy in Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: May 18, 2025
Intervention Type: Drug
Study Drug: N-Acetylcysteine
Study Phase: Phase 1
Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drug: Abexinostat
Study Phase: Phase 2
Phase I/II Clinical Trial of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
Phase I/II Clinical Trial of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: December 14, 2022
Intervention Type: Drug
Study Drugs: Copanlisib, Ibrutinib
Study Phase: Phase 1/Phase 2
Phase Ib Clinical Trial of Buparlisib and Ibrutinib in Mantle Cell Lymphoma, Follicular Lymphoma and Diffuse Large B Cell Lymphoma
Phase Ib Clinical Trial of Buparlisib and Ibrutinib in Mantle Cell Lymphoma, Follicular Lymphoma and Diffuse Large B Cell Lymphoma
Enrollment Status: Completed
Publish Date: October 10, 2022
Intervention Type: Drug
Study Drugs: Buparlisib, Ibrutinib
Study Phase: Phase 1
View 5 Less Clinical Trials

63 Total Publications

Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial.
Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 02, 2025
Similar Doctors
Gail J. Roboz
Elite in Leukemia
Dr. Gail J. Roboz
Hematology Oncology | Oncology | Hematology
Elite in Leukemia
Dr. Gail J. Roboz
Hematology Oncology | Oncology | Hematology

Weill Medical College Of Cornell

520 E 70th St, 
New York, NY 
 (0.1 miles away)
646-962-2012
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gail Roboz is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Roboz is rated as an Elite provider by MediFind in the treatment of Leukemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Elite in Leukemia
Dr. Eytan M. Stein
Hematology | Oncology
Elite in Leukemia
Dr. Eytan M. Stein
Hematology | Oncology

Memorial Hematology Lymphoma Group

530 E 74th St, 
New York, NY 
 (0.3 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eytan Stein is a Hematologist and an Oncologist in New York, New York. Dr. Stein is rated as an Elite provider by MediFind in the treatment of Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Marina Y. Konopleva
Elite in Leukemia
Dr. Marina Y. Konopleva
Hematology Oncology | Hematology | Oncology
Elite in Leukemia
Dr. Marina Y. Konopleva
Hematology Oncology | Hematology | Oncology

Montefiore Medical Center

111 E 210th St, 
Bronx, NY 
 (9.0 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Marina Konopleva is a Hematologist Oncology specialist and a Hematologist in Bronx, New York. Dr. Konopleva is rated as an Elite provider by MediFind in the treatment of Leukemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Batlevi's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile